- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05599347
Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease (AZITRATIM)
November 19, 2023 updated by: Haggai Bar-Yoseph MD, Rambam Health Care Campus
Pre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Crohn's Disease
This is a randomized placebo-controlled trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Anti-TNF agents are considered the mainstay of therapy for patients with inflammatory bowel diseases (IBD).
Still, its efficacy is hampered by the development of anti-drug antibodies (ADA), which lead to non-responsiveness to this medication.
A combination with immunosuppressive agents is currently utilized to reduce ADA development but is accompanied by an increased risk of side effects (i.e.
malignancy and infections).
The investigators have recently found an epidemiologic link between prior antibiotic use and the development of ADA, and shown an antibiotic-specific effect on ADA development in a mouse model.
Macrolide antibiotics were specifically associated with ADA prevention and led to increased durability of the treatment.
Since the microbiome has been associated with the response to anti-TNF therapy, the investigators hypothesize that microbial manipulation with azithromycin prior to the initiation of anti-TNF therapy will lower ADA development.
the investigators propose a randomized controlled study to test our hypothesis and compare it to matched historical cohorts with available clinical and serological data.
The primary outcome will be ADA development at 1 year of therapy.
Study Type
Interventional
Enrollment (Estimated)
180
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Haggai Bar-Yosef, MD
- Phone Number: 050-2064878
- Email: h_bar-yoseph@rmc.gov.il
Study Contact Backup
- Name: Anastasia Weis, MD
- Email: A_WEIS@rambam.health.gov.il
Study Locations
-
-
-
Be'er Sheva, Israel
- Not yet recruiting
- Soroka University Medical Center
-
Contact:
- Doron Schwartz, MD
-
Hadera, Israel
- Not yet recruiting
- Hillel Yaffe Medical Center
-
Contact:
- Baruch Ovadya, MD
-
Haifa, Israel
- Recruiting
- Rambam Health Care Campus
-
Contact:
- Haggai Bar-Yoseph, MD
-
Haifa, Israel
- Recruiting
- Carmel Medical Center
-
Contact:
- Ori Segol, MD
-
Haifa, Israel
- Recruiting
- Bnei Zion
-
Contact:
- Tova Rainis, MD
-
H̱olon, Israel
- Not yet recruiting
- Wolfson Medical Center
-
Contact:
- Eran Israeli, MD
-
Jerusalem, Israel
- Not yet recruiting
- Hadassah Medical Center
-
Contact:
- Lior Katz, MD
-
Jerusalem, Israel
- Recruiting
- Shaare Zedek
-
Contact:
- Ariella Shitrit, MD
-
Kiryat Bialik, Israel
- Not yet recruiting
- Zvulun
-
Contact:
- Reut Lutski, MD
-
Petah Tikva, Israel
- Recruiting
- Rabin Medical Center
-
Contact:
- Iris Dotan
-
Tel Aviv, Israel
- Not yet recruiting
- el Aviv Sourasky Medical Center - Ichilov
-
Contact:
- Haim Leibovitzh, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ability to provide written informed consent prior to any study procedures and willing and able to attend all study visits, comply with the study procedures, read and write in order to complete questionnaires, and be able to complete the study period.
- Aged 18 to 80 years of age, inclusive, at the time of signing the informed consent.
- Diagnosis of CD with an onset of symptoms for a minimum of 3 months prior to Screening as determined by the investigator based on clinical history, exclusion of infectious causes, and characteristic endoscopic and histologic findings.
- Prior decision of starting infliximab or adalimumab therapy (including biosimilar drugs).
- Thiopurine and corticosteroid co-therapy will be permitted.
Exclusion Criteria:
- Inclusion in another interventional study
- Patients who cannot provide informed consent and do not have a legal guardian
- Patients with perianal involvement who are expected to require antibiotic therapy for their disease
- Patients on chronic antibiotic therapy due to any cause
- Patients with ongoing fluid collection/abscess either internal or perianal
- Known history of allergy to the study intervention formulation or any of its excipients or components of the delivery device
- Prolonged QTc interval or conditions leading to additional risk for QT prolongation
- Chronic kidney disease stage 5 (GFR < 10)
- Crohn's Disease complication requiring surgical treatment
- Planned/ongoing methotrexate co-therapy
- Fecal microbiota transplantation within 8 weeks prior to randomization
- Participant has any disorder that, in the opinion of the investigator, may compromise the ability to participate in the study
- Pregnancy
- Patients who received azithromycin therapy in the previous year (we will not exclude prior use of other antibiotic therapy)
- Patients who received any antibiotic treatment within 4 weeks prior to randomization
- Re-induction of the same anti-TNF medication
- Patients who are on chronic therapy which cannot be withheld in one of these medications: colchicine, phenytoin, and digoxin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Azithromycin
5-day consecutive treatment with oral azithromycin 500 mg once daily
|
Tablet - 500 mg azithromycin (as dihydrate)
|
Placebo Comparator: Control
5-day consecutive oral placebo once daily
|
Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-drug antibody development
Time Frame: 1 year after the initiation of therapy
|
Percent of patients developing anti-drug antibodies defined as measurable antibodies using an anti-lambda ELISA assay
|
1 year after the initiation of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sustained corticosteroid-free clinical remission
Time Frame: At both 3 months and a 1 year after the initiation of therapy
|
Crohn's Disease Activity Index (CDAI) ≤150 without systemic corticosteroid therapy
|
At both 3 months and a 1 year after the initiation of therapy
|
Clinical response
Time Frame: 1 year after the initiation of therapy
|
A reduction in CDAI of at least 100 points from baseline.
|
1 year after the initiation of therapy
|
Sustained corticosteroid-free biochemical remission
Time Frame: at both 6 months and a 1 year after the initiation of therapy
|
C-reactive protein (CRP) ≤1.5 upper limit of normal, or fecal calprotectin ≤ 250 mg/kg
|
at both 6 months and a 1 year after the initiation of therapy
|
Treatment durability
Time Frame: at both 6 months and a 1 year after the initiation of therapy
|
Persistent administration of infliximab or adalimumab for 1 year.
A 16-week or more interval between infliximab injections, or an 8-week or more interval between adalimumab injections will be considered as treatment cessation.
Change in anti-TNF regimen at 26 and 52 weeks defined as increased dosing or decreased dosing interval
|
at both 6 months and a 1 year after the initiation of therapy
|
Anti-TNF drug levels
Time Frame: At 6 weeks, 26 weeks and a 1 year after the initiation of therapy
|
Levels at various timepoints
|
At 6 weeks, 26 weeks and a 1 year after the initiation of therapy
|
Early anti-drug antibody development
Time Frame: At 6 weeks, 26 weeks and a 1 year after the initiation of therapy
|
Percent of patients developing anti-drug antibodies defined as measurable antibodies using an anti-lambda ELISA assay
|
At 6 weeks, 26 weeks and a 1 year after the initiation of therapy
|
PRO-2 remission at Week 52
Time Frame: 1 year after the initiation of therapy
|
- Patient reported outcome (PRO-2) remission at Week 52 (defined as an abdominal pain [AP] mean daily score at or below 1 [AP≤1] AND a stool frequency [SF] mean daily score at or below 3 [SF≤3], and no worsening of AP or SF from baseline).
|
1 year after the initiation of therapy
|
Sustained corticosteroid-free PRO-2 clinical remission
Time Frame: At both 14 and a 1 year after the initiation of therapy
|
The rate of sustained corticosteroid-free PRO-2 clinical remission at both 14 and 52 weeks, defined as AP≤1 and SF≤3.
The rate of clinical response at 14 weeks, defined as a reduction in CDAI of at least 100 points from baseline
|
At both 14 and a 1 year after the initiation of therapy
|
Addition of immunomodulator treatment
Time Frame: At any time during the study
|
The rate of addition of immunomodulator treatment defined as at least one dose of thiopurines or methotrexate
|
At any time during the study
|
Immunomodulator treatment termination
Time Frame: At 14 weeks and not restarting by 1 year after the initiation of therapy
|
The rate of immunomodulator treatment termination.
Termination will be defined in patient treated with azathioprine or 6MP at randomization, as being stopped after at least 14 weeks and not restarting by 52 weeks
|
At 14 weeks and not restarting by 1 year after the initiation of therapy
|
Endoscopic improvement
Time Frame: At 26 weeks
|
Endoscopic improvement defined as a reduction of ≥50% decrement from baseline in SES-CD score
|
At 26 weeks
|
Endoscopic remission
Time Frame: At 26 and 52 weeks
|
Endoscopic remission defined as SES-CD ≤4
|
At 26 and 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 24, 2023
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
September 14, 2022
First Submitted That Met QC Criteria
October 25, 2022
First Posted (Actual)
October 31, 2022
Study Record Updates
Last Update Posted (Estimated)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 19, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0432-22-RMB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biological Substance; Adverse Effect
-
Walter Reed National Military Medical CenterUnited States Department of Defense; General Services Administration (GSA)Active, not recruitingAdverse Drug Effect of Opioids | Adverse Drug Effect of BenzodiazepinesUnited States
-
Indiana UniversityNational Institute of General Medical Sciences (NIGMS)CompletedAdverse Effect of Drug Therapy Metabolism Medications (Diagnosis)United States
-
University of Texas Southwestern Medical CenterRecruitingAnesthesia | Anesthesia; Reaction | Anesthesia Complication | Anesthesia; Adverse Effect | Propofol Adverse Reaction | Etomidate Adverse ReactionUnited States
-
Sun Yat-sen UniversityNot yet recruitingArtificial Intelligence | Eye Involvement of Systemic Diseaes | Adverse Drug Effect on Eye
-
Formula30A LLCActive, not recruitingHealth, Subjective | Inflammatory Response | Adverse Effect | Side EffectUnited States, Puerto Rico
-
Assiut UniversityCompletedAdverse Effect of Drug Therapy LevodopaEgypt
-
Wolfson Medical CenterCompleted
-
Companion Dx Reference Lab, LLCUnknownGenetics of Drug MetabolismUnited States
-
Chinese University of Hong KongUniversity of MalayaTerminatedImmunosuppression | Occult Hepatitis B | Biological Substance; Adverse EffectHong Kong
-
General Hospital of Ningxia Medical UniversityCompleted
Clinical Trials on Azithromycin Pill
-
University Hospitals Cleveland Medical CenterThe Cleveland Clinic; MetroHealth Medical CenterRecruitingPremature Birth | Pregnancy Preterm | PROM (Pregnancy) | Pregnancy Prom | PROM, Preterm (Pregnancy) | Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture/LaborUnited States
-
Dr Ian B WilkinsonUniversity College London Hospitals; Imperial College London; Newcastle University and other collaboratorsRecruitingChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
University of SouthamptonRecruitingPertussis/Whooping CoughUnited Kingdom
-
Helsinki University Central HospitalUniversity of Turku; Oulu University Hospital; Kuopio University Hospital; Tampere...RecruitingHysterectomy | Antibiotics | Infection Post Op | ProphylacticFinland
-
CF Therapeutics Development Network Coordinating...Cystic Fibrosis FoundationCompletedCystic FibrosisUnited States, Canada
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Maimónides Biomedical Research Institute of CórdobaRecruitingCovid19 | Acute Respiratory Distress SyndromeSpain
-
DARTNet InstituteUniversity of Colorado, Denver; Icahn School of Medicine at Mount Sinai; Brigham... and other collaboratorsRecruitingRespiratory Tract Infections | Immune System Diseases | Lung Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma | Respiratory HypersensitivityUnited States
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway